Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Emcure Pharmaceuticals Pvt Ltd.

https://www.emcure.com/

Latest From Emcure Pharmaceuticals Pvt Ltd.

Jardiance, Trajenta Wins: Boehringer Takes Rough With Smooth In India

Boehringer Ingelheim tackles infringement activity pertaining to Trajenta and Jardiance in India, at least for now, but more action appears to be in the wings. The private German group remains confident that Jardiance will retain its preferred treatment choice status in the country for type 2 diabetes - but can the blockbuster therapy shake up the heart failure segment as well?

India Commercial

Is India’s Budget Bad News For COVID-19 Boosters, New Vaccines?

India’s 2022-23 budget cuts the outlay for COVID-19 vaccines to a seventh the previous amount. Is that worrying or does it leave the door open for private sales of vaccines? With over 75% of the country's adult population now fully vaccinated, what does it mean for booster shots and yet to be approved SARS-CoV-2 vaccines?

India Coronavirus COVID-19

Generics Industry At The Forefront In War Against COVID-19 In 2021

As the COVID-19 pandemic continued in 2021, the off-patent industry stepped in to provide relief in a variety of ways, whether through securing supplies of essential medicines or helping to manufacture and distribute newly-developed treatments.

Biosimilars Coronavirus COVID-19

2021 Saw India Enable Accelerated Regulatory Pathways – Can It Become The Norm?

India saw a raft of vaccine and drug approvals in 2021, backed by pandemic-related accelerated regulatory processes, and outlined its intent to step up biopharma innovation in the country.  Pharma wants some of the regulatory flexibility to stay, though experts are seeking increased transparency in the overall approach.

Approvals Drug Approval Standards
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
  • Other Names / Subsidiaries
    • Heritage Pharmaceuticals, Zuventus Healthcare
UsernamePublicRestriction

Register